MBX Biosciences
Advancing potential breakthrough medicines for endocrine diseases of substantial medical need.
Launch date
Employees
Market cap
€615m
Enterprise valuation
€565m (Public information from Sep 2024)
Share price
$22.55 MBX
Carmel Indiana (HQ)
Financials
Estimates*
USD | 2022 | 2023 |
---|---|---|
EBITDA | (24.7m) | (32.4m) |
Profit | (26.1m) | (32.6m) |
R&D budget | 21.4m | 28.5m |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $25.3m | Debt | |
$34.6m | Series A | ||
* | $115m | Series B | |
* | $63.5m Valuation: $575m | Series C | |
* | N/A | $188m | IPO |
Total Funding | €194m |
Recent News about MBX Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.